Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 22 Sep 2023
Momelotinib has received FDA approval for the treatment of intermediate or high-risk myelofibrosis, including primary.
Read Full News8 Pulmonology Headlines You Missed in September 2026
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.
AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis
1.
Momelotinib, a JAK inhibitor, has FDA approval to treat adult myelofibrosis in anemic patients.
2.
In schizophrenia, sexual dysfunction is frequent.
3.
UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts
4.
Pancreatic cancer RNA vaccine shows durable T cell immunity
5.
Worse Outcomes After Esophagectomy at Private Equity-Owned Hospitals
1.
AI in the War on Cancer: How Digital Tools are Revolutionizing Oncology
2.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
3.
Polyposis Syndrome: Causes, Symptoms, and Treatment Options
4.
Oncologic Emergencies: Diagnosis and Treatment
5.
Risk Assessment of Neurologic Toxicity From Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
4.
Sickle Cell Disease Explained
5.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge